Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

BACKGROUND: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) and their cyclin partners, is deregulated in cancer. Anti-estrogens, such as tamoxifen, antagonise estrogen-induced ERα transactivation of cyclin D1, resulting in reduced CDK4/6 activity, p27(Kip1)-mediated inhibition of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, N, Bentley, J, Wang, L-Z, Newell, D R, Robson, C N, Shapiro, G I, Curtin, N J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816653/
https://www.ncbi.nlm.nih.gov/pubmed/20010939
http://dx.doi.org/10.1038/sj.bjc.6605479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816653/
https://www.ncbi.nlm.nih.gov/pubmed/20010939
http://dx.doi.org/10.1038/sj.bjc.6605479

Ejemplares similares